Merck & Company Inc. (new) ($MRK) Stock Forecast: Down 1.4% Today

What is Merck & Company Inc. (new)?

Merck & Co., Inc. (MRK) is a leading pharmaceutical company known for its innovative healthcare solutions and strong presence in the market.

Why is Merck & Company Inc. (new) going down?

MRK stock is down 1.4% on Mar 30, 2026 14:42

• Merck (MRK) experienced a bearish movement despite positive news surrounding its recent acquisition of Terns Pharmaceuticals and strong Q4 earnings.
• The increased investment by WESPAC Advisors LLC did not seem to positively impact MRK's stock performance today.
• The growth in the Non-Muscle Invasive Bladder Cancer (NMIBC) market, where Merck is a key player, did not translate into a positive market movement for the company.
• Jim Cramer's advice to "stay the course" with MRK stock did not prevent the bearish trend today, indicating other market factors at play.

MRK Price Chart

MRK Technical Analysis

MRK News

Earnings call transcript: PDS Biotech’s Q4 2025 results show improved financial discipline

PDS Biotechnology Corporation announced its Q4 and full-year 2025 financial results, reporting a reduced net loss of $34.5 million, a $3.1 million improvement year-over-year. The company's stock rose 10.91% in premarket trading due to improved financial discipline and promising clinical trial results for PDS0101, which now has an amended Phase III trial protocol aiming for faster regulatory submission. Executives emphasized cost-cutting measures, advancements in clinical programs, and expanded intellectual property, highlighting PDS0101's potential in treating HPV-16 positive head and neck cancer.

https://www.investing.com/news/transcripts/earnings-call-transcript-pds-biotechs-q4-2025-results-show-improved-financial-discipline-93CH-4587846

WESPAC Advisors LLC Makes New $2.93 Million Investment in Merck & Co., Inc. $MRK

WESPAC Advisors LLC has made a new $2.93 million investment in Merck & Co., Inc. (NYSE:MRK), acquiring 27,798 shares in the fourth quarter. This new position represents about 1.6% of WESPAC Advisors' portfolio and makes Merck its 12th largest holding. The article also highlights Merck's recent acquisition of Terns Pharmaceuticals, strong Q4 earnings, future guidance, and other institutional investment activities.

https://www.marketbeat.com/instant-alerts/filing-wespac-advisors-llc-makes-new-293-million-investment-in-merck-co-inc-mrk-2026-03-30/

Merck (MRK) shares up significantly since Jim Cramer advised to "stay the course"

Merck (MRK) shares have shown significant growth since Jim Cramer advised investors to "stay the course." The article highlights the positive performance of MRK stock, reinforcing Cramer's earlier recommendation.

https://www.msn.com/en-us/money/markets/merck-mrk-shares-up-significantly-since-jim-cramer-advised-to-stay-the-course/ar-AA1ZIxoK?ocid=finance-verthp-feeds

Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Grow

The Non-Muscle Invasive Bladder Cancer (NMIBC) market is projected to grow by $1 billion, reaching $4.82 billion by 2030, led by companies like Johnson & Johnson, Janssen Research & Development, and Merck & Co. This growth is primarily fueled by early diagnosis, increased use of transurethral resection, immunotherapy, chemotherapy, and advancements in personalized medicine. North America currently leads the market, with Asia-Pacific anticipated to show the fastest growth in the coming decade.

https://www.globenewswire.com/news-release/2026/03/30/3264387/0/en/Non-Muscle-Invasive-Bladder-Cancer-NMIBC-Market-to-Grow-by-1-Billion-During-2026-2030-Johnson-Johnson-Janssen-Research-Development-and-Merck-Co-Lead-the-Competition.html

Companion Animal Health Market Forecast 2026-2033 Featuring Strategic Analysis of Agrolabo, Boehringer Ingelheim, Ceva, Elanco, IDEXX Labs and More

The global companion animal health market is projected to grow from USD 25.46 billion in 2025 to USD 56.41 billion by 2033, exhibiting a CAGR of 10.6%. This growth is attributed to advancements in therapeutics and diagnostics, increased awareness of zoonotic diseases, and evolving regulatory frameworks. The report provides a comprehensive analysis including market segmentation by animal, product, distribution channel, and end-use, alongside profiles of key industry players.

https://sg.finance.yahoo.com/news/companion-animal-health-market-forecast-082300955.html

Trending Today

Merck & Company Inc. (new) Price History

25.03.2024 - MRK Stock was up 5.2%

• Merck (MRK) showed a significant upward trend in trading.
• In Q1, the company exceeded expectations with its adjusted earnings.
• The strong sales of Keytruda and vaccines contributed to the positive earnings, prompting an improved company outlook.
• Investor confidence and optimism in Merck's growth and product range were evident in the market's positive response.

30.04.2024 - MRK Stock was down 0.6%

• Merck's agreement to acquire EyeBio for up to $3 billion may have raised concerns among investors about the company's financial health and the potential dilution of shareholder value.
• The market may have reacted negatively to the news of Merck's scientific collaboration deal with Korea's KAIST, as investors might be uncertain about the immediate benefits and long-term implications of this partnership.
• The Chronic Kidney Disease market forecast and the list of companies involved in this sector may have signaled increased competition for Merck, leading to a bearish sentiment among investors.
• Overall, the combination of these developments could have contributed to the bearish movement in Merck's stock today, as investors reevaluated the company's strategic decisions and competitive positioning in the market.

27.02.2024 - MRK Stock was up 5.2%

• Merck's stock experienced a strong bullish trend following the FDA approval of their new treatment for a deadly lung condition, Winrevair, which holds promising market potential.
• The positive outlook towards Merck was also supported by the FDA approval for their drug targeting pulmonary arterial hypertension in adults, demonstrating the company's dedication to creating impactful healthcare solutions.
• The general market recovery and the upsurge in S&P 500 index also played a role in the bullish movement of Merck's stock, reflecting a broader optimism among investors towards the pharmaceutical industry.
• With these recent milestones and endorsements, Merck's innovative approach to healthcare solutions is expected to fuel further growth and investor confidence in the company's future prospects.

03.01.2026 - MRK Stock was up 2.0%

• Merck & Co. (MRK) stock saw an uptick following the release of robust Q4 2025 financial results and positive FY 2026 earnings outlook.
• Optimism surrounds Merck's acquisitions and broad pipeline diversification, especially looking beyond the exclusivity of Keytruda, driving the positive market sentiment.
• An educational campaign by Bristol Myers Squibb and Johnson & Johnson about the factor XIa pathway may be influencing the upward movement, shining a light on the potential of novel anticoagulants for cardiovascular and thromboembolic conditions.
• Positive remarks by Jim Cramer regarding Merck's future prospects and its expansion beyond Keytruda are likely bolstering investor confidence in the company's growth trajectory.

03.01.2026 - MRK Stock was up 6.2%

• Reported impressive Q4 2025 sales and profit figures, beating analyst estimates, driven by strong demand for KEYTRUDA and benefits from recent acquisitions.
• Despite the positive earnings, the cautious 2026 outlook, lower-than-expected guidance, and concerns over the impact of the Cidara acquisition led to initial pre-market stock decline.
• Analysts and experts remain optimistic about Merck's strategic acquisitions, diversified pipeline, and upcoming catalysts, highlighting the company's long-term potential.
• The market seems to be balancing Merck's current financial performance with future growth prospects and potential challenges in specific product sales, such as GARDASIL in China.

30.02.2026 - MRK Stock was down 1.4%

• Merck (MRK) experienced a bearish movement despite positive news surrounding its recent acquisition of Terns Pharmaceuticals and strong Q4 earnings.
• The increased investment by WESPAC Advisors LLC did not seem to positively impact MRK's stock performance today.
• The growth in the Non-Muscle Invasive Bladder Cancer (NMIBC) market, where Merck is a key player, did not translate into a positive market movement for the company.
• Jim Cramer's advice to "stay the course" with MRK stock did not prevent the bearish trend today, indicating other market factors at play.

30.06.2024 - MRK Stock was down 5.3%

• Merck reported strong Q2 earnings with revenue and EPS beating expectations, driven by robust sales of Keytruda, a cancer immunotherapy drug.
• Despite the positive earnings report, the market movement for MRK today could be attributed to concerns over acquisition costs impacting the annual profit forecast, leading to a bearish sentiment among investors.
• The overall market sentiment was slightly positive with US futures rising ahead of major earnings reports and the Federal Reserve meeting, indicating a cautious optimism among investors.
• The news about CrowdStrike dropping in premarket trading due to potential damages sought by Delta Air Lines could have added to the negative sentiment in the market, impacting MRK's stock price.

30.06.2024 - MRK Stock was down 9.5%

• Merck & Co's stock experienced a strong bearish movement today after the company lowered its full-year adjusted profit guidance, causing a significant drop in share price.
• Despite beating earnings per share and revenue expectations for Q2 2024, the market reacted negatively to the lowered guidance for the future, leading to the stock decline.
• Recommendation to buy Merck on the post-earnings dip may indicate a potential opportunity for investors looking at the long-term prospects of the company beyond the current market reaction.
• The broader market sentiment, with investors awaiting the Federal Reserve's policy decision, likely added to the volatility in tech stocks like Merck, contributing to the bearish movement.

30.06.2024 - MRK Stock was down 9.1%

• Merck's Gardasil sales were impacted by China's corruption crackdown, leading to a slowdown in shipments and spooking investors.
• The company's lowered adjusted EPS guidance contributed to the negative sentiment among investors, causing the stock to slide.
• Amidst a mixed day for U.S. equities, Merck stood out with a notable 8% drop, contrasting with the surge in financials and energy stocks.
• The overall sentiment in the biotech sector, to which Merck belongs, was not favorable, as evidenced by the 10% decline in Merck's stock price.

30.06.2024 - MRK Stock was down 9.3%

• Merck & Co exceeded analyst estimates in earnings per share and revenue for Q2 2024, demonstrating robust financial performance.
• The company reduced its adjusted earnings guidance for full-year 2024, causing investor worries and a decline in the market.
• While the Healthcare sector gained, the Technology sector had mixed outcomes. Merck's decline amid positive news from Healthcare sector suggests internal factors affecting its stock performance.
• The Technology sector's variability, including companies like Nvidia facing declines, implies market forces or competitive pressures influencing investor sentiment and contributing to Merck's downturn.

30.06.2024 - MRK Stock was down 10.2%

• Merck (MRK) swung to profit in Q2 on higher revenues, beating earnings expectations. This positive financial performance should have been a bullish indicator for the stock.
• Despite the strong earnings report, Merck (MRK) experienced a notable bearish movement in the market. This could be attributed to potential concerns about acquisition costs impacting the annual profit forecast.
• The mixed results in the Technology sector and the slight dip in major tech players like Nvidia (NVDA) could have influenced overall market sentiment, indirectly affecting Merck's stock price.
• The robust performance of companies like AbbVie (ABBV) in the Healthcare sector might have diverted investor attention away from Merck, contributing to the bearish movement in MRK's stock.

08.00.2026 - MRK Stock was up 3.3%

• Merck's stock price surged following an upgrade from Wolfe Research to Outperform from Peer Perform, showcasing optimism and confidence in the company's growth outlook.
• Identification as a top long-term growth stock by Zacks Investment Research heightened investor interest in Merck, propelling the stock upwards.
• A strategic partnership between Veeva Systems and BioMarin Pharmaceutical, though unrelated to Merck, underlines industry collaborations that could have a positive impact on market sentiment.
• United Asset Strategies Inc. raised its stake in Merck, indicating institutional confidence in the company's future performance and strategic endeavors.